SCHEMBL6637182

SCHEMBL6637182

O=C(c1ccccc1)c1ccccc1NC(Cc1ccc(OCCn2c3ccccc3c3ccccc32)cc1)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.71
PPARA Q07869 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2787981 1.00 PPARG (0.71) PPARGPPARA
Carfloglitazar SCHEMBL29353776 0.94 PPARG (0.65) PPARGPPARA
Chiglitazar SCHEMBL22607975 0.94 PPARG (0.65) PPARGPPARA
Carfloglitazar SCHEMBL10084143 0.94 PPARG (0.65) PPARGPPARA
Chiglitazar SCHEMBL29372245 0.94 PPARG (0.65) PPARGPPARA
SCHEMBL14274956 0.94 PPARG (0.76) PPARGPPARA
SCHEMBL6641515 0.92 PPARG (0.66) PPARGPPARA
SCHEMBL6641508 0.92 PPARG (0.66) PPARGPPARA
SCHEMBL21565295 0.92 PPARG (0.62) PPARGPPARA
SCHEMBL2788918 0.92 PPARG (0.62) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414806-A1 NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC NOVO NORDISK A/S (DK) 2004-05-06 EP claimed
US-20030055076-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2003-03-20 US claimed
WO-2003011834-A1 NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC NOVO NORDISK A/S (DK) 2003-02-13 WO claimed
EP-1569904-B1 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) 2012-01-11 EP disclosed
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity LU XIAN-PING 2008-02-28 US disclosed
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity LU XIAN-PING 2008-02-28 US disclosed
US-7268157-B2 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) 2007-09-11 US disclosed
US-7268157-B2 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) 2007-09-11 US disclosed
EP-1414806-A1 NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC NOVO NORDISK A/S (DK) 2004-05-06 EP disclosed
US-20030055076-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2003-03-20 US disclosed
WO-2003011834-A1 NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC NOVO NORDISK A/S (DK) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055076-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity GPR119, PPARG, PPARA PPARG 2/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.